Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
P/E ratio for Samsung Biologics Co.,Ltd. (207940.KS)
P/E ratio as of 2023: 65.47
According to Samsung Biologics Co.,Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 65.47. At the end of 2022 the company had a P/E ratio of 72.28.
P/E ratio history for Samsung Biologics Co.,Ltd. from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 65.47 |
| 2022 | 72.28 |
| 2021 | 153.41 |
| 2020 | 229.20 |
| 2019 | 142.70 |
| 2018 | 111.59 |
| 2017 | -268.51 |
| 2016 | -50.77 |
| 2015 | 4.24 |
| 2014 | -29.04 |